Last update May 22, 2024

1-(o-Allyloxyphenoxy)-3-isopropylaminopropan-2-ol hydrochloride

Compatible

Safe substance and/or breastfeeding is the best option.

Non-cardioselective beta-blocker indicated in the treatment of hypertension, angina pectoris and cardiac arrhythmias. Oral administration in two or three daily doses.

It is excreted in breast milk in clinically insignificant amounts.(Sioufi 1984, Fidler 1983)

Expert authors consider the use of this medication to be probably compatible during breastfeeding.  (Dennis 2012, Ghanem 2008)

American Academy of Pediatrics: medication usually compatible with breastfeeding.(AAP 2001)

It is a drug that is no longer marketed in many countries.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

1-(o-Allyloxyphenoxy)-3-isopropylaminopropan-2-ol hydrochloride is Oxprenolol Hydrochloride in Chemical name.

Is written in other languages:

1-(o-Allyloxyphenoxy)-3-isopropylaminopropan-2-ol hydrochloride is also known as

Groups

1-(o-Allyloxyphenoxy)-3-isopropylaminopropan-2-ol hydrochloride belongs to these groups or families:

Tradenames

Main tradenames from several countries containing 1-(o-Allyloxyphenoxy)-3-isopropylaminopropan-2-ol hydrochloride in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 40 (20 - 70) %
Molecular weight 265 daltons
Protein Binding 80 - 90 %
VD 1.3 l/Kg
pKa 14.09 -
Tmax 1.5 (0.5 - 2) hours
T½ 1 - 3 hours
M/P ratio 0.2 - 0.4 -
Theoretical Dose 0.02 - 0.07 mg/Kg/d
Relative Dose 0.8 - 1.8 %

References

  1. Dennis AT. Management of pre-eclampsia: issues for anaesthetists. Anaesthesia. 2012 Sep;67(9):1009-20. Abstract Full text (link to original source) Full text (in our servers)
  2. Tamargo Menéndez J, Delpón Mosquera E. Farmacología de los bloqueantes de los receptores β-adrenérgicos. Curso βeta 2011 de Actualización en Betabloqueantes. 2011 Full text (in our servers)
  3. Ghanem FA, Movahed A. Use of antihypertensive drugs during pregnancy and lactation. Cardiovasc Ther. 2008 Abstract Full text (link to original source) Full text (in our servers)
  4. AAP - American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001 Sep;108(3):776-89. Abstract Full text (link to original source) Full text (in our servers)
  5. Riant P, Urien S, Albengres E, Duche JC, Tillement JP. High plasma protein binding as a parameter in the selection of betablockers for lactating women. Biochem Pharmacol. 1986 Abstract
  6. Sioufi A, Hillion D, Lumbroso P, Wainer R, Olivier-Martin M, Schoeller JP, Colussi D, Leroux F, Mangoni P. Oxprenolol placental transfer, plasma concentrations in newborns and passage into breast milk. Br J Clin Pharmacol. 1984 Sep;18(3):453-6. Abstract
  7. Fidler J, Smith V, De Swiet M. Excretion of oxprenolol and timolol in breast milk. Br J Obstet Gynaecol. 1983 Oct;90(10):961-5. Abstract

Total visits

691

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM